The effect of hydroxyurea on the coagulation system in sickle cell anemia and β-thalassemia intermedia patients: A preliminary study

Pediatric Hematology and Oncology

Volumn 20, Issue 6, 2003, Pages 429-434

  Koc, A ^a   Gumruk, F ^a   Gurgey, Aytemiz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Coagulation factors; Factor VIII; Hydroxy area; Protein C

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CREATINE; HEMOGLOBIN F; HYDROXYUREA; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD CLOTTING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOPENIA; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PROTHROMBIN TIME; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; VEIN OCCLUSION;

EID: 0042427770     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390220090     Document Type: Article

References (21)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crisis in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
2. Koren A, Segal-Kupershmit D, Zalman L, et al. Effect of hydroxyurea in sickle cell anemia and sickle cell beta-thalassemia. Pediatr Hematol Oncol. 1999;16:221-232.
3. Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Blood Cells MolDis. 2000;26:453-466.
4. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550-1554.
5. Ballas SK, Marcolina MJ, Dover GJ, Barton FB. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol. 1999;105:491-496.
6. Maier-Redelsperger M, de Montalembert M, Flahault A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood. 1998;91:4472-4479.
7. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 1994;71:169-172.
8. Leslie J, Langler D, Serjeant GR, Sergeant BE, Desai P, Gordon YB. Coagulation changes during steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol. 1975;30:159-166.
9. Karayalcin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol OncoL 1989;11:320-323.
10. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis. 1995;6:93-99.
11. Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105-111.
12. Oner AF, Gurgey A, Okur H, Kirazli S, Gumruk F, Alyay C. Changes of hemostatic factors in patients with hemoglobinopathies. Tukr J Pediatr. 1999;41:323-327.
13. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood. 1994;83:553-560.
14. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999;102:31-37.
15. Liesner, R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol. 1998;103:1037-1040.
16. Francis RB. Protein S deficiency in sickle cell anemia. J Lab Clin Med. 1988;111:571-576.
17. Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol. 2000;22:330-334.
18. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002;140:225-229.
19. de Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol. 1997; 19:313-318.
20. Vokes EE, Stenson K, Rosen FR, et al. Weeky carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21:320-326.
21. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152-155.